ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.670,79
0,28%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Transition Therapeutics - Ordinary Shares (TTHI)

  7. Transition Therapeutics - Ordinary Shares (TTHI) News

TTHI

Transition Therapeutics - Ordinary Shares (TTHI)

Transition Therapeutics - Ordinary Shares
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:TTHI
DatumZeitQuelleÜberschriftSymbolFirma
11/10/201619h51Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
13/09/201623h16Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
13/09/201623h14Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
09/09/201620h04Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
31/08/201614h56Edgar (US Regulatory)(25-NSE)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
31/08/201612h31Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
31/08/201607h00Business WireOPKO Health Completes Acquisition of Transition TherapeuticsNASDAQ:TTHITransition Therapeutics - Ordinary Shares
26/08/201614h52Business WireTransition Therapeutics Shareholders Approve Acquisition by OPKO HealthNASDAQ:TTHITransition Therapeutics - Ordinary Shares
26/08/201612h02Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
26/08/201600h46PR Newswire (US)Transition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Ar...NASDAQ:TTHITransition Therapeutics - Ordinary Shares
26/08/201600h46PR Newswire (Canada)Transition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Ar...NASDAQ:TTHITransition Therapeutics - Ordinary Shares
04/08/201622h07Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
13/07/201622h55Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
06/07/201623h31Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
30/06/201614h15Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
30/06/201608h00Business WireOPKO Health to Acquire Transition TherapeuticsNASDAQ:TTHITransition Therapeutics - Ordinary Shares
03/06/201615h03Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
03/06/201612h01PR Newswire (Canada)Transition Therapeutics Receives Notification From NASDAQNASDAQ:TTHITransition Therapeutics - Ordinary Shares
03/06/201612h01PR Newswire (US)Transition Therapeutics Receives Notification From NASDAQNASDAQ:TTHITransition Therapeutics - Ordinary Shares
11/05/201622h37Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
11/05/201622h01PR Newswire (Canada)Transition Therapeutics Announces Third Quarter Fiscal 2016 Financial ResultsNASDAQ:TTHITransition Therapeutics - Ordinary Shares
11/05/201622h01PR Newswire (US)Transition Therapeutics Announces Third Quarter Fiscal 2016 Financial ResultsNASDAQ:TTHITransition Therapeutics - Ordinary Shares
09/05/201623h45Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
09/05/201622h01PR Newswire (Canada)Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:3...NASDAQ:TTHITransition Therapeutics - Ordinary Shares
09/05/201622h01PR Newswire (US)Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:3...NASDAQ:TTHITransition Therapeutics - Ordinary Shares
26/04/201615h30Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
25/04/201622h01PR Newswire (Canada)Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701NASDAQ:TTHITransition Therapeutics - Ordinary Shares
25/04/201622h01PR Newswire (US)Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701NASDAQ:TTHITransition Therapeutics - Ordinary Shares
18/04/201615h05Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:TTHITransition Therapeutics - Ordinary Shares
18/04/201612h01PR Newswire (US)Transition Therapeutics Provides Update on Type 2 Diabetes Drug Candidate TT401NASDAQ:TTHITransition Therapeutics - Ordinary Shares
 Showing the most relevant articles for your search:NASDAQ:TTHI

Kürzlich von Ihnen besucht

LSE
80GG
Hsbc Bk 31
TSXV
LPC
Lorne Park Capital Partn...
LSE
GMA
Gma Resources
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten